Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bone Metastases
Interventions: BIOLOGICAL: Denosumab|DRUG: Zoledronic Acid
Sponsor: Amgen